0P5I
vs
D
DAX Index
0P5I
Over the past 12 months, 0P5I has significantly outperformed DAX Index, delivering a return of +138% compared to the DAX Index's +17% growth.
Stocks Performance
0P5I vs DAX Index
Performance Gap
0P5I vs DAX Index
Performance By Year
0P5I vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Mauna Kea Technologies SAS
Glance View
Mauna Kea Technologies SA engages in the design, development, and sale of optical biopsy devices and tools to visualize and detect abnormalities in the gastro-intestinal and pulmonary tracts primarily in cancer patients. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2011-07-05. The firm focuses on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product is Cellvizio, a confocal laser endomicroscopy platform using microprobes and needles. This technological platform enables to view tissues at cellular level, in real time, during standard procedure. Cellvizio can be used in gastroenterology, pulmonology, or urology. The firm markets its technological platform in more than 40 countries, including the United States, Europe, Japan, China, South Korea as well as several Latin American countries.
